24/7 Market News Snapshot 19 December, 2024 – Bio-Path Holdings Inc (NASDAQ:BPTH)

December 19, 2024

DENVER, Colo., 19 December, 2024 (247marketnews.com) – (NASDAQ:BPTH) are discussed in this article.
Bio-Path Holdings Inc. (NASDAQ:BPTH) is experiencing a significant surge in its stock, currently priced at $1.30, reflecting an impressive increase of 95.07% from the previous close of $0.67 in the pre-market session. This notable rise is accompanied by a substantial trading volume of 6.82 million shares, indicating heightened investor interest and confidence in the company’s prospects.

This enthusiasm follows the announcement of encouraging preclinical study results for Bio-Path’s drug candidate, BP1001-A, which is being evaluated for its potential to treat obesity and related metabolic disorders, particularly in individuals with Type 2 diabetes. Recent findings illustrate that BP1001-A significantly improves insulin sensitivity by modulating the growth factor receptor-bound protein 2 (Grb2), a pivotal element in insulin signaling. Data from these studies reveal a marked reduction in Grb2 protein expression while also increasing phosphorylated AKT and FOXO-1 levels in myoblast and hepatoma cells exposed to insulin treatment. This mechanism positions BP1001-A as a promising new option for effectively managing blood glucose levels and enhancing metabolic responses among obese patients struggling with Type 2 diabetes.

Peter H. Nielsen, President and CEO of Bio-Path, expressed optimism regarding these initial findings that reinforce BP1001-A’s therapeutic potential. He highlighted the urgent need for innovative weight management treatments, given the existing limitations of current pharmacological options. Bio-Path is advancing its research with the initiation of animal studies, laying the foundation for a first-in-human Phase 1 clinical trial anticipated in 2025. This trial aims to rigorously assess the drug’s safety, pharmacokinetics, and suitable dosing regimens.

As Bio-Path Holdings continues to forge ahead with its innovative approach to targeted cancer therapies and metabolic disorder treatments, stakeholders are encouraged to monitor developments closely as the company works towards delivering transformative healthcare solutions.

Related news for (BPTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.